OVID - オ―ビッド・セラピュ―ティクス （Ovid Therapeutics Inc.） オ―ビッド・セラピュ―ティクスOVIDのチャート
OVIDの企業情報
| symbol | OVID |
|---|---|
| 会社名 | Ovid Therapeutics Inc （オ―ビッド・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 オービッド・セラピューティクス（Ovid Therapeutics Inc.）はバイオ医薬品企業。同社はまれな神経学的障害患者ための医薬品の開発に従事する。同社のリード薬剤候補はOV101で、第2のリードドラッグ候補はOV935である。OV101（ガボクサドール）はデルタ選択的なGABAA受容体作用薬である。同社が潜在的に持続性抑制を回復させ、障害症状を緩和するために、アンジェルマン症候群と脆弱X症候群に応用するOV101は現在開発中である。同社はアンジェルマン症候群の成人でOV101の第II相STARS試験とアンジェルマン症候群または脆弱X症候群の若者でPhase I試験を開始した。同社は武田薬品工業と協力して、まれなてんかん性脳症の治療薬OV935を開発する。 オ―ビッド・セラピュ―ティクスは米国のバイオ医薬品企業。主に中枢神経系疾患の治療薬の開発を行う。候補薬には、アンジェルマン症候群及び脆弱X症候群を対象とした「OV101」、そしてドラベ症候群、レノックス・ガスト―症候群、結節性硬化症などの希少てんかん性脳症を対象とする「OV935」(TAK-935)がある。本社はニューヨーク。 ovid therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. ovid’s drug candidate, ov101, is currently in development for the treatment of symptoms of angelman syndrome and fragile x syndrome. ovid is also developing ov935 in collaboration with takeda pharmaceutical company limited for the treatment of rare epileptic encephalopathies. ovid has initiated the phase 2 stars trial of ov101 in adults with angelman syndrome and a phase 1 trial in adolescents with angelman and fragile x syndrome to identify doses suitable for younger patients. review our community guidelines: http://www.ovidrx.com/community-guidelines/ |
| 本社所在地 | 1460 Broadway Suite 15044 New York NY 10036 USA |
| 代表者氏名 | Jeremy Max Levin ジェレミーマックスレビン |
| 代表者役職名 | Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者 |
| 電話番号 | +1 646-661-7661 |
| 設立年月日 | 41730 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2017年 |
| 従業員数 | － |
| url | www.ovidrx.com |
| nasdaq_url | https://www.nasdaq.com/symbol/ovid |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -46.99967 |
| 終値（lastsale） | 5.99 |
| 時価総額（marketcap） | 147545554.21 |
| 時価総額 | 時価総額（百万ドル） 151.73300 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 89.13840 |
| 当期純利益 | 当期純利益（百万ドル） -36.89227 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Ovid Therapeutics Inc revenues was not reported. Net loss decreased 41% to $26.1M. Lower net loss reflects Research and development decrease of 56% to $16.6M (expense) Interest income increase from $63K to $522K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$3.18 to -$1.06. |
OVIDのテクニカル分析
OVIDのニュース
Ovid Therapeutics: Q1 Earnings Insights 2023/05/05 13:25:09 Benzinga
Ovid Therapeutics (NASDAQ: OVID ) reported its Q1 earnings results on Friday, May 5, 2023 at 07:30 AM. Here''s what investors need to know about the announcement. Earnings Ovid Therapeutics missed estimated earnings by 11.76%, reporting an EPS of $-0.19 … Full story available on Benzinga.com
Ovid Therapeutics GAAP EPS of -$0.19 misses by $0.02, revenue of $0.07M beats by $0.05M 2023/05/05 11:56:36 Seeking Alpha
Ovid Therapeutics press release (NASDAQ:OVID): Q1 GAAP EPS of -$0.19 misses by $0.02.Revenue of $0.07M (-95.2% Y/Y) beats by $0.05M.
Ovid Therapeutics Announces Long-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study Presented by Takeda 2023/04/27 18:33:02 Investing.com
https://www.investing.com/news/assorted/ovid-therapeutics-announces-longterm-safety--efficacy-findings-from-soticlestat-open-label-extension-study-presented-by-takeda-432SI-3066691
Ovid Therapeutics Inc PT Raised to $2.50 at Citi 2023/03/15 20:40:05 Investing.com
https://www.investing.com/news/pro/ovid-therapeutics-inc-pt-raised-to-250-at-citi-432SI-3031625
Looking Into Ovid Therapeutics''s Return On Capital Employed 2023/03/15 14:47:48 Benzinga
According to Benzinga Pro data, during Q4, Ovid Therapeutics (NASDAQ: OVID ) posted sales of $46 thousand. Earnings were up 3.87%, but Ovid Therapeutics still reported an overall loss of $11.50 million. In Q3, Ovid Therapeutics brought in $11 thousand in sales but lost $11.97 million in earnings. Why Is ROCE Significant? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a … Full story available on Benzinga.com
Ovid Therapeutics Inc PT Raised to $2.50 at Citi 2023/03/15 20:40:05 Investing.com
https://www.investing.com/news/pro/ovid-therapeutics-inc-pt-raised-to-250-at-citi-432SI-3031625
Looking Into Ovid Therapeutics''s Return On Capital Employed 2023/03/15 14:47:48 Benzinga
According to Benzinga Pro data, during Q4, Ovid Therapeutics (NASDAQ: OVID ) posted sales of $46 thousand. Earnings were up 3.87%, but Ovid Therapeutics still reported an overall loss of $11.50 million. In Q3, Ovid Therapeutics brought in $11 thousand in sales but lost $11.97 million in earnings. Why Is ROCE Significant? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a … Full story available on Benzinga.com
Ovid Therapeutics GAAP EPS of -$0.16 beats by $0.02 2023/03/13 12:20:27 Seeking Alpha
Ovid Therapeutics press release (OVID): Q4 GAAP EPS of -$0.16 beats by $0.02.Cash, cash equivalents and marketable securities as of December 31, 2022 totaled $129.0 million.
Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results 2023/03/13 12:00:00 GlobeNewswire
NEW YORK, March 13, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2022.
Ovid Therapeutics Earnings, Revenue Beat in Q3 By Investing.com 2022/11/08 21:11:00 Investing.com
Ovid Therapeutics Earnings, Revenue Beat in Q3
Ovid Therapeutics Earnings, Revenue Beat in Q3 By Investing.com 2022/11/08 21:11:00 Investing.com
Ovid Therapeutics Earnings, Revenue Beat in Q3
Ovid Therapeutics GAAP EPS of -$0.17 beats by $0.04 2022/11/08 13:57:29 Seeking Alpha
Ovid Therapeutics press release (OVID): Q3 GAAP EPS of -$0.17 beats by $0.04.Revenue of $11.1K.The company ended Q3 with cash, cash equivalents and marketable securities of…
Ovid Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights 2022/11/08 13:00:00 GlobeNewswire
NEW YORK, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today reported financial results and corporate highlights for the third quarter ended September 30, 2022.
Ovid Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference 2022/09/07 12:00:00 GlobeNewswire
NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that management will present at the H.C. Wainwright 24 th Annual Global Investment Conference in New York, New York on Monday, September 12, 2022, at 12:00 p.m. ET.